AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

Summary

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Type 2 Diabetes
• Cardiovascular Risk

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

45 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Novo Nordisk A/S

Last updated on ClinicalTrials.gov

September 1, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites